Palvella Therapeutics, Inc. (PVLA) News
Track canonical SquawkNews coverage tagged to PVLA, Palvella Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
PVLA - Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PVLA - Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 04, 2026, 11:30 AM UTC
L
PVLA - Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurp
PVLA - Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
REGULATION | Jul 30, 2026, 11:30 AM UTC
L
H.C. Wainwright says Palvella selloff 'an overreaction' to FDA's BTD denial
H.C. Wainwright notes...
EQUITY | Jul 21, 2026, 05:12 PM UTC
M
Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Mi
Palvella Therapeutics submits first module of rolling NDA to FDA for QTORIN 3.9% rapamycin anhydrous gel approval
REGULATION | Jun 29, 2026, 11:33 AM UTC
M
PVLA: FDA Starts Review
Palvella Therapeutics announces FDA rolling review of its new drug application for Qtorin Rapamycin
EQUITY | Jun 22, 2026, 11:41 AM UTC
H
PVLA: FDA Grants Rolling Review
Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations receives rolling review from FDA
EQUITY | Jun 22, 2026, 11:30 AM UTC